Supernus announces FDA accepted resubmission of SPN-830 NDA; PDUFA date Feb 1, 2025

SUPERNUS PHARMACEUTICALS, INC.

FDA acknowledged resubmission of NDA for SPN-830 (apomorphine infusion device) for continuous treatment of motor fluctuations in Parkinson's disease.
Resubmission is considered filed; user fee goal date (PDUFA) set for February 1, 2025.
SPN-830 targets OFF episodes in Parkinson's disease; Supernus focuses on CNS therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.